Bullish On Books
- The Five Myths of Private Equity
- Financial and Career Advice for Women Offered in New Book by ‘Mrs. Moneypenny’
- Just in Time for the Super Bowl, Authors of ‘Scorecasting’ Ask if Defense Truly Wins Championships
- ‘All Business is Local’ - New Book Offers Survival Tips for Going and Growing Global Businesses
- Authors of ‘The Challenger Sale’ say Building Relationships No Longer Works
- Author of ‘Getting from College to Career’ With 5 Best Strategies for Finding a Job Now
- Author of ‘The Psychology of Wealth’ on Your Mind and Wallet
- Are You and Your Business Ready for the ‘Precovery’
- Life on Wall Street Now - Secrets of a ‘Bond Girl’
- Apple's iBooks 2 Revolution - Not What You Think
MOST SHARED
- FTSE, DAX, CAC Seen Lower, Greek Deal Delayed
- India's December Industrial Output Growth Slows Sharply
- Bonus Bloodbath as European Banker Backlash Continues
- Greece Deal Fails to Convince, EU Demands More
- Strip Greenspan of His Knighthood: SocGen Strategist
- Zynga, Hasbro Partner to Make Toys, Games
- Jobs You Can Do Forever
- Citigroup Takes $50 Million Loss in Libor Probe
- New York Fashion Week Hits the Runway as Colors Pop
- Mulling Buffett's Stock Advice? Get in With REITs: Fund Managers
- LinkedIn Earnings Bode Well for Hiring and Social Media
- Top Five Mistakes to Avoid in Online Dating
- Victor Cruz ‘Understands’ Gisele's Super Bowl Frustrations
- Tamminen: The United States of India
- Unusual Volume: Taleo Jumps After Oracle's $1.9 Billion Offer
- Warren Buffett: Stocks Will Outperform Gold and Bonds .. and They're Safer 'By Far'
- So Now You Can’t Give Microsoft Away?
- Citigroup Takes $50 Million Loss in Lending Rate Probe
- Investment Banking Drags Down Barclays Profit
- The Secret Lives of Traders—Seeking the Next Hot Thing
- FBI Investigated Steve Jobs Drug Use

- Strip Greenspan of His Knighthood: SocGen Strategist
- China Imports Slump, Raising Demand Concerns
- Markets Finally Get Greek Deal —So Where's the Rally?
- Warren Buffett: Stocks Will Outperform Gold and Bonds
- Get All the Latest Out of Europe Here
RSS FEED
Toyota's Congressional Hearing: 'How Risky Is It'
Guest Author Blog: David Ropeik is a consultant in risk communication and author of How Risky Is It, Really? Why Our Fears Don’t Always Match the Facts, to be published in March by McGraw Hill.
![]() |
Getty Images |
Toyota is falling all over itself apologizing for flaws in its vehicles.
They are running TV ads as part of an effort to “restore your faith in our company”.
They ran an OpEd in the Washington Post, in which company president Akio Toyoda personally apologized and said he wants to “restore trust in our word and in our products”.
Toyota is doing the right thing.
Now.
But as someone who studies the way people perceive risk, and the importance of trust to those perceptions, it continues to amaze me how many smart successful firms like Toyota manage to forget the importance of trust until they’re in trouble, and then they have to spend huge amounts of money and effort, for years, trying to rebuild it.
As in so many cases, Toyota’s [TM
Loading...
()
] mistake was not with the product itself.
Sure, flawed brake pedals and accelerators that stick are enough to shake people’s faith in the product. But faith in the company is threatened more by word that Toyota had to be pushed by U.S. regulators to recall their flawed vehicles, after knowing about the problems for years. And not for the first time. The Los Angeles Times, which helped break the story about the accelerator problem, also reported that Toyota was less than forthcoming when they discovered an accelerator problem in Sienna minivans in 2003, fixing it in new vehicles but not telling those who already owned one about the problem.
![]() |
It’s about the corporate attitude.
And Toyota is not alone.
Merck’s [MRK
Loading...
()
] problems with Vioxx were significantly worse because the company allegedly knew about, but didn’t report, problems with their drug. Or consider the Guidant Corporation. In 2005 Guidant knew one of their popular heart defibrillators had some sort of a problem, but didn’t report it to doctors and patients. The New York Times did, suggesting that Guidant was putting profits over patient safety. Prior to the news, Johnson and Johnson [JNJ
Loading...
()
] had offered to buy Guidant for $25 billion. Within a few weeks of the news reports, the offer dropped to $21 billion. (Guidant’s CEO “retired early” 6 weeks later.) Sales of defibrillators, from all manufacturers, were off for months.
It’s not about the products.
It’s about the deceit.
It’s about a corporate attitude toward risk management that forgets the risk to the company when it is not honest with its customers. It’s about a myopic lawyer-driven protectiveness of the bottom line that ignores the incredible risk a company takes when it forgets how hard it is to build trust and how easy, and phenomenally costly it is, to destroy it.
When it comes to the perception of risk, little shapes our fears more than trust.
Do we trust the company making the product? Do we trust the industry that company is a part of (the pharmaceutical industry, the chemical industry)? Do we trust the regulators who are supposed to protect us from unsafe products? If we trust, we will be less afraid. If we don’t, our fears will be higher. When it appears that a company is protecting itself and its profits at the expense of our health, trust, even if there was plenty there beforehand, goes straight down the toilet. Welcome to Toyota 2010, the latest version of this incredibly common corporate mistake.
There is an interesting model in medicine that demonstrates a fundamental lesson about trust. In several states, laws allow doctors to apologize for mistakes, without that apology being used against them in court. Apologies in those jurisdictions are up, and not surprisingly, malpractice lawsuits are dramatically down. Why? It’s not the apology per se. It’s being treated honestly, openly, with respect. It’s having our feelings and concerns taken seriously. It’s someone putting their own self-interest second, and ours first. That’s why apologies work.
Toyota’s apologies are a step in the right direction. But they will not be enough.
Trust, once damaged, is not easily restored, especially when the issue involves threats to our safety. How the company behaves going forward, not only with their products but how they handle the lawsuits they face over the injuries and deaths their products and secrecy allegedly caused, will matter more than the right words.
Ads and OpEds won’t help Toyota all that much, but tangible proof of a change in corporate attitude just might.
_______________________________________

David Ropeik is a consultant in risk communication and author of How Risky Is It, Really? Why Our Fears Don’t Always Match the Facts, to be published in March by McGraw Hill.
To read more now, check out the author's Web site.
____________________
Do you have a book suggestion?
Email me at — And follow me on Twitter @BullishonBooks











